InSilico Medicine Cayman TopCo (03696) Announces Monthly Return for January 2026

Bulletin Express02-05

InSilico Medicine Cayman TopCo (03696) maintained an authorized share capital of USD 635, comprising 1,270,000,000 ordinary shares at a par value of USD 0.0000005 each. As of January 31, 2026, the company reported an increase in its issued ordinary shares (excluding treasury shares) from 557,418,500 to 571,622,000, reflecting an addition of 14,203,500 shares.

The company confirmed compliance with its minimum public float requirement of 15%. Share issuance activity included a full exercise of the Over-allotment Option on January 21, 2026, involving 14,203,500 shares issued at HKD 24.05.

Under the relevant equity incentive plans, 31,595,520 share options were outstanding at the end of the prior month, with 24,058 options lapsed, leaving 31,571,462. The company also reported a Post-IPO Share Option Scheme and RSU Scheme, with no newly issued shares during January 2026 but a continuing ability to issue shares under these plans.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160885073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160885073","market":"us","top_or_hot":-1,"title":"InSilico Medicine Cayman TopCo (03696) Announces Monthly Return for January 2026","media":"Bulletin Express","content":"<p>InSilico Medicine Cayman TopCo (03696) maintained an authorized share capital of USD 635, comprising 1,270,000,000 ordinary shares at a par value of USD 0.0000005 each. As of January 31, 2026, the company reported an increase in its issued ordinary shares (excluding treasury shares) from 557,418,500 to 571,622,000, reflecting an addition of 14,203,500 shares.</p>\n<p>The company confirmed compliance with its minimum public float requirement of 15%. Share issuance activity included a full exercise of the Over-allotment Option on January 21, 2026, involving 14,203,500 shares issued at HKD 24.05.</p>\n<p>Under the relevant equity incentive plans, 31,595,520 share options were outstanding at the end of the prior month, with 24,058 options lapsed, leaving 31,571,462. The company also reported a Post-IPO Share Option Scheme and RSU Scheme, with no newly issued shares during January 2026 but a continuing ability to issue shares under these plans.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InSilico Medicine Cayman TopCo (03696) Announces Monthly Return for January 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInSilico Medicine Cayman TopCo (03696) Announces Monthly Return for January 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-05 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>InSilico Medicine Cayman TopCo (03696) maintained an authorized share capital of USD 635, comprising 1,270,000,000 ordinary shares at a par value of USD 0.0000005 each. As of January 31, 2026, the company reported an increase in its issued ordinary shares (excluding treasury shares) from 557,418,500 to 571,622,000, reflecting an addition of 14,203,500 shares.</p>\n<p>The company confirmed compliance with its minimum public float requirement of 15%. Share issuance activity included a full exercise of the Over-allotment Option on January 21, 2026, involving 14,203,500 shares issued at HKD 24.05.</p>\n<p>Under the relevant equity incentive plans, 31,595,520 share options were outstanding at the end of the prior month, with 24,058 options lapsed, leaving 31,571,462. The company also reported a Post-IPO Share Option Scheme and RSU Scheme, with no newly issued shares during January 2026 but a continuing ability to issue shares under these plans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1160885073","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160885073","pubTimestamp":1770282002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"InSilico Medicine Cayman TopCo (03696) maintained an authorized share capital of USD 635, comprising 1,270,000,000 ordinary shares at a par value of USD 0.0000005 each. As of January 31, 2026, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"InSilico Medicine Cayman TopCo(03696)公布2026年1月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"InSilico Medicine Cayman TopCo (03696) maintained an authorized share capital of USD 635, comprising 1,270,000,000 ordinary shares at a par value of USD 0.0000005 each. As of January 31, 2026, the company reported an increase in its issued ordinary shares (excluding treasury shares) from 557,418,500 to 571,622,000, reflecting an addition of 14,203,500 shares.\nThe company confirmed compliance with its minimum public float requirement of 15%. Share issuance activity included a full exercise of the Over-allotment Option on January 21, 2026, involving 14,203,500 shares issued at HKD 24.05.\nUnder the relevant equity incentive plans, 31,595,520 share options were outstanding at the end of the prior month, with 24,058 options lapsed, leaving 31,571,462. The company also reported a Post-IPO Share Option Scheme and RSU Scheme, with no newly issued shares during January 2026 but a continuing ability to issue shares under these plans.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160885073","isCrawlerRequest":true}